Abstract
The effect of a single intramuscular injection of deferoxamine mesylate, a potent iron chelating agent, on six-hour urinary iron excretion was used as a simplified screening test for iron-storage disease. Sixteen normal, 12 diabetic, and 12 iron-overload patients were studied. The diabetic group showed a significant decrease in transferrin and in pre- and post-deferoxamine urinary iron excretion. Eleven patients in the iron-overload group exhibited varied but marked increase in serum iron levels and in pre- and post-deferoxamine urinary iron excretion. The 12th subject had iron deficiency as the result of many phlebotomies; the deferoxamine-test results were corroborated by absence of iron on liver biopsy. A range of values was proposed to set limits for normal and iron-overload groups.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
